Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 433-480-9 | CAS number: 623-53-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: official guideline method, GLP with certificate, good and extensive documentation, identity of substance clear but no details on its purity
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 001
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- -
- EC Number:
- 433-480-9
- EC Name:
- -
- Cas Number:
- 623-53-0
- Molecular formula:
- C4H8O3
- IUPAC Name:
- ethyl methyl carbonate
- Details on test material:
- Test material as stated in study report ("Sponsor's identification"): MEC
Description: clear colourless liquid
Lot number: 009141
Date received: 11.27.2000
Storage conditions: stored at room temperature in the dark until 01.16.2001, thereafter stored at 4 °C in the dark
Remark of the author of this IUCLID dossier concerning the substance identity:
Every page of the copy of the study report contains an annotation referring to the data sharing agreement in place between the licensee that uses this study report and the data owner. In this data sharing agreement the identity of the chemical substance is specified with "Ethyl Methyl Carbonate - EC No. 433-480-9, CAS Nr. 623-53-0".
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Sprague-Dawley Crl:CD (registered trademark) IGS BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Forty (Twenty males and twenty females) Sprague-Dawley Crl:CD(R) (SD) IGS BR strain rats of good health were used in the study.
Animal delivery from Charles River (UK) Limited, Margate, Kent.
Animal weight before study: males 125-163 g, females 126-150 g
Animal age: approximately five to six weeks
Acclimatisation period: 8 d
Animal identification: uniquely identified by ear punching system
Husbandry: groups of 5, separation by sex, polypropylene grid-floor cages suspended over trays lined with absorbent paper, drinking water (in polycarbonate bottles attached to cage) and food ad libitum (pelleted diet: Rat Mouse SQC Expanded Diet No. 1, Special Diets Services Limited, Witham, Essex, UK), wooden chew blocks in cages (B & K Universal Ltd., Hull, UK). Drinking water and diet were considered to be free of any contaminants that would have affected the study results. Temperature: 21 +/- 2 °C, relative humidity 55 +/- 15 %, light-darkness cycle 12 h/12 h (low intensity fluorescent lighting), at least 15 air changes/h.
The animals were randomly allocated to treatment groups using random letter tables and the group mean body weights were then determined to ensure similarity between treatment groups. The cage distribution within the holding rack was also randomised.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: Arachis oil BP
- Details on oral exposure:
- The test material was administered daily, for twenty-eight consecutive days, by gavage using a stainless steel cannula attached to a disposable plastic syringe. Control animals were treated in an identical manner with 2 mL/kg/day of Arachis oil BP.
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- by gavage to three groups, each of five male and five female Sprague-Dawley Crl:CD(R) (SD) IGS BR strain rats, for twenty-eight consecutive days
- Frequency of treatment:
- The test material was administered daily.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 15, 150, 1000 mg/kg/day
Basis:
other: concentrations of test substance in Arachis oil BP
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- Clinical observations: All animals were examined for overt signs of toxicity, ill-health or behavioural change immediately before dosing and one and five hours after dosing during the working week. Animals were observed immediately before dosing and one hour after dosing at weekends. All observations were recorded.
Functional/behavioural toxicity observations: gait, tremors, twitches, convulsions, bizarre/abnormal/stereotypic behaviour, salivation, pilo-erection, exophtalmia, lachrymation, hyper/hypothermia, skin colour, respiration, palebral closure, urination, defecation, transfer arousal, tail elevation; motor activity assessment, forelimb/hindlimb grip strength, sensory reactivity: grasp response, vocalisation, toe pinch, tail pinch, finger approach, touch escape, pupil reflex, startle reflex, blink reflex.
Monitoring of food and water intake and body weights throughout the study.
Haematological and blood chemical investigations: haemoglobin, erythrocyte count, haematocrit, erythrocyte indices, total leukocyte count, differential leukocyte count, platelet count, reticulocyte count (cresyl blue stained slides prepared but reticulocytes not assessed), prothrombin time (by Hepato Quick), Activated partial thromboplastin time (by Preci Clot); urea, glucose, total protein, albumin, albumin/globulin ratio, sodium, potassium, chloride, calcium, inorganic phosporus, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, creatinine, total cholesterol, total bilirubin
Pathology: after dosing experiment animals killed by intravenous overdose sodium pentobarbitone; followed by exsanguination.
full external and internal examination; recording of macroscopic abnormalities: adrenals, brain, epididymides, heart, kidneys, liver, ovaries, spleen, testes, thymus; histopathology (exminations by Precision Histology International, Norfolk, UK): adrenals, aorta (thoracic), bone & bone marrow (femur incl. stifle joint, sternum), brain (incl. cerebrum, cerebrellum and pons), caecum, colon, duodenum, epididymides, eyes, gross lesions, heart, ileum, jejunum, oesophagus, ovaries, testes, pancreas, pituitary, prostate, rectum, salivary glands (submaxillary), sciative nerve, seminal vesicles, skin (hind limb), spinal cord (cervical), spleen, stomach, kidneys, liver, lungs (with bronchi), lymph nodes (cervical and mesenteric), muscle (skeletal), thymus, thyroid/parathyroid, trachea, urinary bladder, uterus
Extensive statistical evaluation of data including: group mean values, standard deviations, ANOVA, Levene's test, Dunnett's test, Kruskal-Wallis ANOVA, Mann-Whitney 'U' test. p >= 0.05 considered as not significant
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- for male rats confined to 1000 mg/kg/day, for eather sex treated with 150 or 15 mg/kg/day
- Mortality:
- no mortality observed
- Description (incidence):
- for male rats confined to 1000 mg/kg/day, for eather sex treated with 150 or 15 mg/kg/day
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- no adverse effect on bw development was detected
- Food consumption and compound intake (if feeding study):
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- no treatment-related effects were detected
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- no toxicologically significant effects were detected
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Sex:
- male
- Dose descriptor:
- NOEL
- Effect level:
- 150 mg/kg bw/day (nominal)
- Sex:
- female
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Summary of results:
Oral administration of the test material, MEC to rats for a period of twenty-eight consecutive days at dose levels of up to 1000 mg/kg/day produced minor treatment-related changes confined to 1000 mg/kg/day females. No such effects were demonstrated in males treated with 1000 mg/kg/day or animals of either sex treated with 150 mg/kg/day or 15 mg/kg/day.
Mortalities: none
Clinical observations: Clinical signs were confined to 1000 mg/kg/d females who showed an isolated instance of increased salivation detected up to ten minutes after dosing on Day 5 and hunched posture from Day 14 onwards. It was further concluded in the study report that in view of the isolated nature and absence of supporting evidence to the contrary these findings was considered to be of dubious toxicological significance. No treatment-related clinical signs were detected in 1000 mg/kg/day males or animals of either sex treated with 150 or 15 mg/kg/d.
Behavioural Assessements: Detailed open-field observations confirmed the clinical signs of hunched posture detected in 1000 mg/kg/d females from Week 2 onwards. No effects were detected in 1000 mg/kg/d males or in animals of either sex treated with 150 or 15 mg/kg/d. All remaining inter and intra group differences in behavioural scores were considered to be a result of normal variation for rats of the strain and age used and were of no toxicological importance.
Functional Performance Tests: There were no treatment-related changes in the functional performance parameters measured. Statistical analysis of the data revealed no significant intergroup differences
Sensory Reactivity Assessments: There were no treatment-related changes in sensory reactivity. All inter and intra group differences in sensory reactivity scores were considered a result of normal variation for rats of the strain and age used and were of no toxicological importance. Statistical analysis of the quantitative data revealed no significant intergroup differences.
Blood Chemistry: There were no treatment-related changes detected in the blood chemical parameters measured. Statistical analysis of the data revealed no significant intergroup differences.
Pathology:
Necropsy: No treatment-related macroscopic abnormalities were detected.
Histopathology: There were no treatment-related microscopic changes observed.
Applicant's summary and conclusion
- Conclusions:
- No effects were demonstrated in male rats treated with 1000 mg/kg/day or animals of either sex treated with 150 mg/kg/day or 15 mg/kg/day. The "No Observed Effect Level" was considered to be 1000 mg/kg/day in males and 150 mg/kg/day in females.
The substance does not need to be classified according to REGULATION (EC) No 1272/2008 (of 16 Dec 2008), 3.9. Specific target organ toxicity — repeated exposure. The highest concentration range for oral exposure (in a 90-d study) that justifies classification when significant toxic effects are observed is 10 < C ≤ 100 mg/kg bw/d. The lowest NOEL is above this range in this study (150 mg/kg bw/d) and furthermore for classification 90-d-study data would be required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.